Сравнение
LL-37 vs. Pasireotid
Два пептида рядом — идентичность, доказательная база, правовой статус и известные нежелательные явления.
Идентичность
Категория
Исследования (прочее)
Исследования (прочее)
Номер CAS
597562-32-8
396091-73-9
Молекулярная масса
4493.33 g/mol
1047.21 g/mol
Период полувыведения
нет данных
нет данных
Последовательность
LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTESнет данных
Механизм действия
LL-37
LL-37 is a cationic, amphipathic helical peptide and the only member of the cathelicidin family in humans. It is generated by proteolytic cleavage from the C-terminal portion of the precursor protein hCAP18 (CAP-18). Mechanistically it associates with and can permeabilize microbial membranes; in addition it modulates immune cells, influences cytokine release, exerts chemotactic activity, and can bind extracellular self-DNA. Preclinical models have described both anti-inflammatory and pro-inflammatory effects, depending on concentration and tissue context.
Pasireotid
Pasireotide binds more broadly than older somatostatin analogs (SSTR1/2/3/5) with particularly high affinity for SSTR5. This suppresses, among others, ACTH release in Cushing's disease and GH release in acromegaly.
Доказательная база
Наивысшая доказательность
Исследование на людях
РКИ на людях
Исследования
4
1
из них на людях
1
1
Зафиксированные эффекты
4
2
Открытые противоречия
1
0
Задокументированные нежелательные явления
0
2
Правовой статус
Полные записи
Frequently asked questions
- What is the difference between LL-37 and Pasireotid?
- LL-37 is classified as "Исследования (прочее)", while Pasireotid is classified as "Исследования (прочее)". LL-37: LL-37 is the only known human cathelicidin, a 37-amino-acid antimicrobial peptide generated by cleavage of the precursor protein hCAP18. In research it plays a central role in innate immune defence and wound healing, yet acts in a context-dependent manner as both anti- and pro-inflammatory and has been linked to autoimmune processes. LL-37 is not an approved drug; the evidence base is predominantly basic and preclinical. Pasireotid: Pasireotide is a multireceptor somatostatin analog binding to four of the five somatostatin receptors (especially SSTR5). It is approved for Cushing's disease and acromegaly. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, LL-37 or Pasireotid?
- The highest available evidence level is "Исследование на людях" for LL-37 and "РКИ на людях" for Pasireotid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of LL-37 and Pasireotid in Germany and the United States?
- Германия: LL-37 — Только для исследований, Pasireotid — Рецептурный. США: LL-37 — Только для исследований, Pasireotid — Рецептурный. These are factual summaries with source and review date on the individual pages.